PTH and osteoporosis: In terms of residual effects after discontinuation, bisphosphonates are distinct from other anti-osteoporosis agents including estrogen, raloxifene, parathyroid hormone, and receptor activator of NF-κB ligand (RANKL) inhibitors, such as denosumab.